Ovarian cancer, the coagulation pathway, and inflammation

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Wang, Xipeng ^a   Wang, Ena ^b   Kavanagh, John J ^a   Freedman, Ralph S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; CHEMOKINE; COMPLEMENTARY DNA; COUMARIN DERIVATIVE; CYTOKINE; DALTEPARIN; DOCETAXEL; ENOXAPARIN; EPITHELIAL PROTEIN C RECEPTOR; FIBRINOGEN; HEPARIN; HEPARIN COFACTOR II; INTERLEUKIN 8; KALLIKREIN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PROTEINASE ACTIVATED RECEPTOR; REGULATOR PROTEIN; THROMBIN; THROMBIN RECEPTOR; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN;

ADVANCED CANCER; ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; ASCITES; ASTHENIA; BLEEDING; BLOOD CLOTTING; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; CELL PROLIFERATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DNA MICROARRAY; DRUG MECHANISM; FEMALE; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MICROENVIRONMENT; NEUTROPENIA; OUTCOMES RESEARCH; OVARY CANCER; PERITONEUM METASTASIS; REVIEW; THROMBOSIS; TUMOR VASCULARIZATION; UNITED STATES; UPREGULATION;

EID: 27344452904     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-25     Document Type: Review

References (203)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Feeley KM, Wells M: Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38:87-95.
3. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM: Peritoneal and Subperitoneal Stroma May Facilitate Regional Spread of Ovarian Cancer. Clin Cancer Res 2005, 11:113-122.
4. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD: Cadherin switching in ovarian cancer progression. Int J Cancer 2003, 106:172-177.
5. Roskelley CD, Bissell MJ: The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 2002, 12:97-104.
6. Freedman RS, Deavers M, Liu J, Wang E: Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med 2004, 2:23.
7. Dvorak HF, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
8. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004, 101:4966-4971.
9. A. T: Phlegmasia alba dolens: Clinique medicale de l'Hotel-Dieu de Paris. 2nd ed. paris,. Fance: JBBalliere et Fils 1865:654-712.
10. Sampson MT, Kakkar AK: Coagulation proteases and human cancer. Biochem Soc Trans 2002, 30:201-207.
11. Rickles FR, Levine M, Edwards RL: Hemostatic alterations in cancer patients. Cancer Metastasis Rey 1992, 11:237-248.
12. Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W, Kudryk BJ: Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993, 85:1225-1230.
13. Naschitz JE, Yeshurun D, Lev LM: Thromboembolism in cancer. Changing trends. Cancer 1993, 71:1384-1390.
14. Schmeidler-Sapiro KT, Ratnoff OD, Gordon EM: Mitogenic Effects of Coagulation Factor XII and Factor XIIa on HepG2 Cells. PNAS 1991, 88:4382-4385.
15. Borgono CA, Diamandis EP: The emerging roles of human tissue kallikreins in cancer. Nat Rey Cancer 2004, 4:876-890.
16. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Trope C, Saatcioglu F: Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol 2004, 94:80-85.
17. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diamandis EP: Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003, 63:3958-3965.
18. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP: Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003, 63:2223-2227.
19. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Katsaros D: Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003, 21:1035-1043.
20. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW: Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 2004, 91:725-731.
21. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA: Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003, 9:1710-1720.
22. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP: The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001, 7:806-811.
23. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP: Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003, 63:2771-2774.
24. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D: Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res 2001, 61:7811-7818.
25. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP: Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 2001, 7:2372-2379.
26. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RCJ, Gershenson DM, Schmandt R: Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 2003, 90:44-50.
27. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP: The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003, 63:807-811.
28. Borgono CA, Fracchioli S, Yousef GM, Rigault de la Longrais IA, Luo LY, Soosaipillai A, Puopolo M, Grass L, Scorilas A, Diamandis EP, Katsaros D: Favorable prognostic value of tissue human kallikrein II (hKII) in patients with ovarian carcinoma. Int J Cancer 2003, 106:605-610.
29. Diamandis EP, Borgono CA, Scorilas A, Harbeck N, Dorn J, Schmitt M: Human kallikrein II: an indicator of favorable prognosis in ovarian cancer patients. Clin Biochem 2004, 37:823-829.
30. Shigemasa K, Gu L, Tanimoto H, O'Brien TJ, Ohama K: Human kallikrein gene II (KLKII) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin Cancer Res 2004, 10:2766-2770.
31. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N: Human kallikrein II: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002, 62:295-300.
32. Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP: Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol 2004, 22:678-685.
33. Kapadia C, Ghosh MC, Grass L, Diamandis EP: Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun 2004, 323:1084-1090.
34. Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D, Diamandis EP: Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003, 63:9032-9041.
35. Yousef GM, Fracchioli S, Scorilas A, Borgono CA, Iskander L, Puopolo M, Massobrio M, Diamandis EP, Katsaros D: Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 2003, 119:346-355.
36. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, Rigault de la Longrais IA, Puopolo M, Massobrio M, Diamandis EP: Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 2003, 21:3119-3126.
37. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C: Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004, 90:686-692.
38. Deperthes D, Frenette G, Brillard-Bourdet M, Bourgeois L, Gauthier F, Tremblay RR, Dube JY: Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 1996, 17:659-665.
39. Webber MM, Waghray A, Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995, 1:1089-1094.
40. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP: Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 2003, 307:948-955.
41. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS: Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 1999, 81:438-442.
42. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC, Madeddu P: Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001, 103:125-132.
43. Wolf WC, Evans DM, Chao L, Chao J: A Synthetic Tissue Kallikrein Inhibitor Suppresses Cancer Cell Invasiveness. Am J Pathol 2001, 159:1797-1805.
44. Kamath L, Meydani A, Foss F, Kuliopulos A: Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001, 61:5933-5940.
45. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, Moreau T: Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001, 268:2960-2968.
46. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL: Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999, 91:1663-1669.
47. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P: Differential Expression of Protease-Activated Receptors-1 and -2 in Stromal Fibroblasts of Normal, Benign, and Malignant Human Tissues. Am J Pathol 2001, 158:2031-2041.
48. Seligsohn U: Factor XI deficiency. Thromb Haemost 1993, 70:68-71.
49. Podmore A, Smith M, Savidge G, Alhaq A: Real-time quantitative PCR analysis of factor Xi mRNA variants in human platelets. J Thromb Haemost 2004, 2:1713-1719.
50. Bazan JF: Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A 1990, 87:6934-6938.
51. Carson SD, Bromberg ME: Tissue factor encryption/de-encryption is not altered in the absence of the cytoplasmic domain. Thromb Haemost 2000, 84:657-663.
52. Edgington TS, Mackman N, Brand K, Ruf W: The structural biology of expression and function of tissue factor. Thromb Haemost 1991, 66:67-79.
53. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996, 271:17629-17634.
54. Bartha K, Brisson C, Archipoff G, de la Salle C, Lanza F, Cazenave JP, Beretz A: Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem 1993, 268:421-429.
55. Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL: Fibrin induction of tissue factor expression in human vascular endothelial cells. Circulation 1997, 96:605-613.
56. Fang J, Wei WN, Liu ZP, Song SJ: [Cloning of expression vector of human tissue factor gene and its expression in human ovarian cancer cell line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003, 11:579-582.
57. Fang J, Wei WN, Xia LH, Song SJ: [The effects of tissue factor/activated factor VII complex on the invasion and metastasis of human ovarian cancer.]. Zhonghua Xue Ye Xue Za Zhi 2004, 25:523-527.
58. Fang J, Wei WN, Xia LH, Song SJ: [Study of the effect of TF/FVIIa complex on the expression of u-PAR mRNA in human ovarian cancer]. Zhonghua Xue Ye Xue Za Zhi 2004, 25:143-146.
59. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T: Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000, 83:164-170.
60. Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru K, Yoshizawa Y: Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999, 79:472-477.
61. Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, Shiku H: Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002, 69:247-254.
62. Ueda C, Hirohata Y, Kihara Y, Nakamura H, Abe S, Akahane K, Okamoto K, Itoh H, Otsuki M: Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J Gastroenterol 2001, 36:848-850.
63. Lwaleed BA, Cooper AJ: Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu. Med Hypotheses 2000, 55:470-473.
64. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
65. Fernandez PM, Rickles FR: Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002, 9:401-406.
66. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994, 94:1320-1327.
67. Shoji M, Abe K, Nawroth PP, Rickles FR: Molecular Mechanisms Linking Thrombosis and Angiogenesis in Cancer. Trends in Cardiovascular Medicine 1997, 7:52-59.
68. Sorensen BB, Freskgard PO, Nielsen LS, Rao LV, Ezban M, Petersen LC: Factor Vila-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem 1999, 274:21349-21354.
69. Camerer E, Huang W, Coughlin SR: Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 2000, 97:5255-5260.
70. Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H: Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995, 270:4650-4660.
71. Camerer E, Rottingen JA, Iversen JG, Prydz H: Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996, 271:29034-29042.
72. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W: Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004, 10:502-509.
73. Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister B, Ikomi F, Tritsaris K, Dissing S, Ohhashi T, Jackson DG, Cao Y: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004, 6:333-345.
74. Sevinsky JR, Rao LV, Ruf W: Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996, 133:293-304.
75. Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LV, Ruf W: Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000, 20:874-882.
76. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM: Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993, 69:366-369.
77. Ahamed J, Belting M, Ruf W: Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor-1. Blood 2004.
78. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS: Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003, 63:2997-3000.
79. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002, 87:930-936.
80. Sprecher CA, Kisiel W, Mathewes S, Foster DC: Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A 1994, 91:3353-3357.
81. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, Goggins M: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinom. Oncogene 2004.
82. Chand HS, Du X, Ma D, Inzunza HD, Kamei S, Foster D, Brodie S, Kisiel W: The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004, 103:1069-1077.
83. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S, Rao JS: Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001, 7:570-576.
84. Mueller BM, Reisfeld RA, Edgington TS, Ruf W: Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992, 89:11832-11836.
85. Mueller BM, Ruf W: Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998, 101:1372-1378.
86. Versteeg HH, Sorensen BB, Slofstra SH, Van den Brande JH, Stam JC, van Bergen en Henegouwen PM, Richel DJ, Petersen LC, Peppelenbosch MP: VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. J Biol Chem 2002, 277:27065-27072.
87. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP: Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004, 23:410-417.
88. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC: Antiapoptotic effect of coagulation factor VIIa. Blood 2003, 102:1708-1715.
89. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV: Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004, 103:3029-3037.
90. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Trope CG, Bryne M, Risberg B, van de Putte G, Goldberg I: Interieukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis 2002, 19:135-144.
91. Gawrychowski K, Skopinska-Rozewska E, Barcz E, Sommer E, Szaniawska B, Roszkowska-Purska K, Janik P, Zielinski J: Angiogenic activity and interleukin-8 content of human ovarian cancer ascites. Eur J Gynaecol Oncol 1998, 19:262-264.
92. Mukaida N: Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 2003, 284:L566-77.
93. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R: Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998, 4:909-914.
94. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R: Differential expression of Protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 2005, 113:372-378.
95. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME: Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993, 264:C1302-7.
96. Tsopanoglou NE, Maragoudakis ME: On the mechanism of thrombin-induced angiogenesis: inhibition of attachment of endothelial cells on basement membrane components. Angiogenesis 1998, 1:192-200.
97. Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Wakimaru N, Nakata M, Kitajima I, Maruyama I: The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor. Int J. Oncol 2002, 20:921-928.
98. Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997, 94:663-668.
99. Tsopanoglou NE, Maragoudakis ME: On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by upregulation of its receptors. J Biol Chem 1999, 274:23969-23976.
100. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S: Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002, 99:1646-1650.
101. Herbert JM, Dupuy E, Laplace MC, Zini JM, Bar Shavit R, Tobelem G: Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J 1994, 303 ( Pt 1):227-231.
102. Coughlin SR: Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
103. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, D'Andrea MR, Andrade-Gordon P, Karpatkin S: Protease-activated receptor I (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998, 92:3694-3700.
104. Henrikson KP, Salazar SL, Fenton JW, Pentecost BT: Role of thrombin receptor in breast cancer invasiveness. Br J Cancer 1999, 79:401-406.
105. Hughes PE, Pfaff M: Integrin affinity modulation. Trends Cell Biol 1998, 8:359-364.
106. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF: A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985, 101:880-886.
107. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
108. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S: Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991, 87:229-236.
109. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M: Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003, 162:1503-1513.
110. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S: Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004, 104:2746-2751.
111. Asanuma K, Wakabayashi H, Hayashi T, Okuyama N, Seto M, Matsumine A, Kusuzaki K, Suzuki K, Uchida A: Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology 2004, 67:166-173.
112. Liu J, Schuff-Werner P, Steiner M: Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells. FEBS Lett 2004, 577:175-180.
113. Walz DA, Fenton JW: The role of thrombin in tumor cell metastasis. Invasion Metastasis 1994, 14:303-308.
114. Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P, Bar-Shavit R: Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem 2001, 276:10952-10962.
115. Vial E, Sahai E, Marshall CJ: ERK-MAPK signaling coordinately regulates activity of RacI and RhoA for tumor cell motility. Cancer Cell 2003, 4:67-79.
116. Conner SR, Scott G, Aplin AE: Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem 2003, 278:34548-34554.
117. Tellez C, Bar-Eli M: Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003, 22:3130-3137.
118. Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, Bar-Eli M, Duvic M: Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res 2004, 64:7361-7369.
119. Booden MA, Eckert LB, Der CJ, Trejo J: Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol 2004, 24:1990-1999.
120. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM: Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004, 2:395-402.
121. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR: Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004, 104:397-401.
122. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR: Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem 2002, 277:16081-16087.
123. Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng A, Griffin C, Coughlin SR: Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 2003, 102:3224-3231.
124. Dallabrida SM, Falls LA, Farrell DH: Factor XIIIa supports micro-vascular endothelial cell adhesion and inhibits capillary tube formation in fibrin. Blood 2000, 95:2586-2592.
125. Cox AD, Devine DV: Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 1994, 83:1006-1016.
126. Barry EL, Mosher DF: Binding and degradation of blood coagulation factor XIII by cultured fibroblasts. J Biol Chem 1990, 265:9302-9307.
127. Wilhelm O, Hafter R, Henschen A, Schmitt M, Graeff H: Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 1990, 75:1673-1678.
128. Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF: Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995, 55:369-375.
129. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF: Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 1995, 55:376-385.
130. van de Molengraft F, Jap P, Poels L, Croes H, Vooijs P: Tumor cell settling and early invasion of the peritoneum. Clin Exp Metastasis 1989, 7:187-199.
131. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995, 55:360-368.
132. Nagy JA, Herzberg KT, Masse EM, Zientara GP, Dvorak HF: Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res 1989, 49:5448-5458.
133. Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996, 2:209-215.
134. Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE: Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 2000, 60:4719-4724.
135. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove A, Lemmens J, Vermeulen P: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002, 86:389-395.
136. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C: Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000, 18:600-608.
137. van Hinsbergh VW, Collen A, Koolwijk P: Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 2001, 936:426-437.
138. Clark RA, Tonnesen MG, Gailit J, Cheresh DA: Transient functional expression of alpha Vbeta 3 on vascular cells during wound repair. Am J Pathol 1996, 148:1407-1421.
139. Maekawa H, Sato H, Tollefsen DM: Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex. Thromb Res 2000, 100:443-451.
140. Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM: Complete nucleotide sequence of the gene for human heparin cofactor II and mapping to chromosomal band 22q11. Biochemistry 1991, 30:1350-1357.
141. Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton JW, Andrew M, Delorme M, Ginsberg J, Preissner KT, et al.: Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995, 73:405-412.
142. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM: Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002, 109:213-219.
143. Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, Tamura K, Matsumoto T: High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 2004, 109:481-486.
144. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, Yoshida T, Hashizume S, Kato M, Yamaguchi H, Kato S, Ikeda Y, Arase T, Kondo A, Matsumoto T: Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 2004, 109:2761-2765.
145. Pratt CW, Tobin RB, Church FC: Interaction of heparin cofactor 11 with neutrophil elastase and cathepsin G. J Biol Chem 1990, 265:6092-6097.
146. Church FC, Pratt CW, Hoffman M: Leukocyte chemoattractant peptides from the serpin heparin cofactor II. J Biol Chem 1991, 266:704-709.
147. Simmonds RE, Lane DA: Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: comparison with the structure of CD 1/major histocompatibility complex alpha1 and alpha2 domains. Blood 1999, 94:632-641.
148. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT: Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997, 100:411-418.
149. Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H, Kimoto M: Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med 1998, 187:1029-1035.
150. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW: Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001, 276:11199-11203.
151. Van de Wouwer M, Collen D, Conway EM: Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004, 24:1374-1383.
152. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003, 9:338-342.
153. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation of endothelial cell protease activated receptor I by the protein C pathway. Science 2002, 296:1880-1882.
154. Esmon CT: Structure and functions of the endothelial cell protein C receptor. Crit Care Med 2004, 32:S298-301.
155. Kurosawa S, Esmon CT, Stearns-Kurosawa DJ: The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000, 165:4697-4703.
156. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S: A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004, 103:1311-1318.
157. Medina P, Navarro S, Estelles A, Vaya A, Woodhams B, Mira Y, Villa P, Migaud-Fressart M, Ferrando F, Aznar J, Bertina RM, Espana F: Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb Haemost 2004, 91:905-911.
158. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, Esmon CT: Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998, 91:725-727.
159. Iwaki T, Cruz DT, Martin JA, Castellino FJ: A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. Blood 2004.
160. Scheffer GL, Flens MJ, Hageman S, Izquierdo MA, Shoemaker RH, Scheper RJ: Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer 2002, 38:1535-1542.
161. Tsuneyoshi N, Fukudome K, Horiguchi S, Ye X, Matsuzaki M, Toi M, Suzuki K, Kimoto M: Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost 2001, 85:356-361.
162. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L: Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998, 160:5130-5135.
163. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon N, Esmon CT, Coughlin SR: PARI cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 2005.
164. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD: Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 2000, 6:2268-2278.
165. Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S: Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 1994, 16:198-210.
166. Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD: Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 1994, 167:145-160.
167. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
168. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschraegen CF, Platsoucas CD, Freedman RS: Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. Clin Exp Immunol 1998, 112:172-180.
169. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, Whiteside TL: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996, 68:276-284.
170. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
171. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J: Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002, 277:24584-24593.
172. Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, Allavena P, Sozzani S, Mantovani A, Balkwill FR: The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995, 95:2391-2396.
173. Negus RP, Stamp GW, Hadley J, Balkwill FR: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997, 150:1723-1734.
174. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J: Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002, 8:1108-1114.
175. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM: Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004, 10:4427-4436.
176. Opala T, Drews K, Rzymski P, Wozniak J, Sajdak S: Evaluation of soluble intracellular adhesion molecule-1 (sICAM-1) in benign and malignant ovarian masses. Eur J Gynaecol Oncol 2003, 24:255-257.
177. Esmon CT: Inflammation and thrombosis. J Thromb Haemost 2003, 1:1343-1348.
178. Esmon CT: Coagulation and inflammation. J Endotoxin Res 2003, 9:192-198.
179. Esmon CT: Interactions between the innate immune and blood coagulation systems. Trends Immunol 2004, 25:536-542.
180. Esmon CT: Crosstalk between inflammation and thrombosis. Maturitas 2004, 47:305-314.
181. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999, 96:2311-2315.
182. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000, 96:170-175.
183. Esmon CT: The impact of the inflammatory response on coagulation. Thromb Res 2004, 114:321-327.
184. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ: Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988, 263:18205-18212.
185. Gear AR, Camerini D: Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003, 10:335-350.
186. Miller DL, Yaron R, Yellin MJ: CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 1998, 63:373-379.
187. Fujisawa T, Fujisawa R, Kato Y, Nakayama T, Morita A, Katsumata H, Nishimori H, Iguchi K, Kamiya H, Gray PW, Chantry D, Suzuki R, Yoshie O: Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol 2002, 110:139-146.
188. Fukudome K, Esmon CT: Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994, 269:26486-26491.
189. Conway EM, Rosenberg RD: Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988, 8:5588-5592.
190. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999, 130:800-809.
191. Abildgaard U: Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993, 23 Suppl 1:103-106.
192. Green D, Hull RD, Brant R, Pineo GF: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992, 339:1476.
193. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996, 100:269-277.
194. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR: Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999, 82:947-952.
195. Cosgrove RH, Zacharski LR, Racine E, Andersen JC: Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002, 28:79-87.
196. Kakkar AK, Williamson RC: Antithrombotic therapy in cancer. Bmj 1999, 318:1571-1572.
197. Zacharski LR, Ornstein DL, Mamourian AC: Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000, 26 Suppl 1:69-77.
198. Wojtukiewicz MZ, Kozlowski L, Ostrowska K, Dmitruk A, Zacharski LR: Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost 2003, 89:405-407.
199. Robert F, Busby E, Marques MB, Reynolds RE, Carey DE: Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer 2003, 42:237-245.
200. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJJ, Forcier RJ, Edwards RL, Headley E, Kim SH, O'Donnell JF, et al.: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984, 53:2046-2052.
201. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RCN: Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004, 22:1944-1948.
202. Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN: Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism. J Clin Oncol 2005:JCO.2005.03.133.
203. Schulman S, Lindmarker P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000, 342:1953-1958.